Patent intelligence · US
US 12053444
Therapeutic compounds, formulations, and uses thereof
Therapeutic compounds, formulations, and uses thereof
Patent details — US 12053444
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2024
- Expiration
- Aug 1, 2044
- Applicant
- Tvardi Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/18, A61K47/10, A61K47/26
Quick answer
US 12053444 (Therapeutic compounds, formulations, and uses thereof) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tvardi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/18, A61K47/10, A61K47/26, A61K47/44, A61K9/0053
More from Tvardi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12053444?
US 12053444 (Therapeutic compounds, formulations, and uses thereof) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12053444?
Tvardi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12053444 expire?
Our index shows an expiration date of Aug 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.